The largest community of pharma leaders

Lubrizol Life Science Health Awarded Grant for Generic Contraceptive Injection Research to Advance Women’s Health Worldwide

BETHLEHEM, Pa.–()–The Lubrizol Corporation has announced that the contract development and manufacturing organization (CDMO) of Lubrizol Life Science Health (LLS Health) has been awarded a grant to support its research on injectable contraceptive formulations designed to bring accessible contraceptive products to women in developing nations.

Around 220 million women in developing countries lack access to contraceptives and voluntary family planning information and services1. It is hoped that through funding from the Bill & Melinda Gates Foundation a contraceptive injection can be developed and manufactured in a format to allow for user self-administration to improve access.

“LLS Health has built in-depth expertise of the physicochemical characteristics involved in the development of complex formulations, including long-acting injectable products, so we are well-positioned to assist the foundation,” said Dr. Robert Lee, president, CDMO Division, LLS Health. “This research will set the foundation for more accessible contraceptive products in developing nations and we look forward to continued partnership with the foundation to achieve our joint missions.”

This project is the second phase of an ongoing program with the foundation. LLS Health will manufacture batches of the injection formulation, placing them on a five-year stability program to assess the shelf life. A longer shelf life can positively affect the affordability of a drug product. The program’s first phase sought to identify the critical quality attributes for acceptable resuspendability of high concentration suspension formulations and develop a process to manufacture the drug product.

The research program links to the Lubrizol Corporation’s ‘Live Better’ mission, which pledges to improve at least 2 billion lives by 2028 through utilizing its formulating expertise, testing capabilities, market insights and global scale.

“Today, more than ever, people around the world realize that health and wellness are essential to our quality of life,” said Barbara Morgan, general manager for the LLS Health CDMO Division. “Our team is at the forefront of drug product innovation. By utilizing LLS Health’s formulating expertise, we are helping develop products that enable billions of people to live better, bringing Lubrizol’s mission to life.”

About The Lubrizol Corporation

The Lubrizol Corporation, a Berkshire Hathaway Company, leverages its unmatched science to unlock immense possibilities at the molecular level, driving sustainable and measurable results to help the world Move Cleaner, Create Smarter and Live Better. Founded in 1928, Lubrizol owns and operates more than 100 manufacturing facilities, sales and technical offices around the world and has approximately 8,800 employees. For more information, visit

For more information on the CDMO Division of Lubrizol Life Science Health, visit




Recent Articles

TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a prespecified exploratory analysis of the positive...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.